BioCentury | Feb 28, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain; inflammation; sleep disorders Fatty acid amide hydrolase (FAAH) An SAR study identified a-ketooxazole analogs as FAAH inhibitors that could be...
BioCentury | Dec 17, 2007
Clinical News

ASF-1057: Phase III started

Astion began an international Phase III trial in 500 patients with moderate to severe facial seborrheic dermatitis to compare ASF-1057 vs. neutral moisturizing cream or placebo. Astion Pharma A/S , Copenhagen, Denmark Product: ASF-1057 Business: Dermatology...
BioCentury | Dec 17, 2007
Clinical News

ASF-1057: Phase III started

Astion began an international Phase III trial in 700 patients with moderate to severe facial seborrheic dermatitis to compare topical ASF-1057 vs. 2% ketoconazole cream or placebo. Astion Pharma A/S , Copenhagen, Denmark Product: ASF-1057 Business:...
BioCentury | Oct 30, 2006
Clinical News

ASF-1057: Phase IIb started

Astion began a double-blind, placebo-controlled, French Phase IIb trial (Study 204) in 104 patients. Subjects will receive 1 of 3 doses of ASF-1057 or placebo once-daily for 3 weeks. Astion Pharma A/S , Copenhagen, Denmark Product:...
BioCentury | Oct 30, 2006
Clinical News

ASF-1057: Phase IIb start

By year end, Astion will begin a double-blind, placebo-controlled, French Phase IIb trial (Study 205) in 60 patients. Subjects will receive 1 of 2 doses of ASF-1057 or placebo twice-daily for 3 weeks. Astion Pharma...
BioCentury | Oct 30, 2006
Clinical News

ASF-1057: Phase IIb start

Early next year, Astion will begin a double-blind, placebo-controlled, U.K. Phase IIb trial (Study 206) in 100 patients. Astion Pharma A/S , Copenhagen, Denmark Product: ASF-1057 Business: Dermatology Molecular target: NA Description: Non-steroidal anti-inflammatory compound that...
Items per page:
1 - 6 of 6